Review





Similar Products

apatinib  (MedChemExpress)
97
MedChemExpress apatinib
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib/product/MedChemExpress
Average 97 stars, based on 1 article reviews
apatinib - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
apatinib  (Jiangsu Hengrui Medicine)
90
Jiangsu Hengrui Medicine apatinib
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib/product/Jiangsu Hengrui Medicine
Average 90 stars, based on 1 article reviews
apatinib - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
apatinib  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals apatinib
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib/product/MultiTarget Pharmaceuticals
Average 90 stars, based on 1 article reviews
apatinib - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
apatinib jiangsu hengrui co  (Jiangsu Hengrui Medicine)
90
Jiangsu Hengrui Medicine apatinib jiangsu hengrui co
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib Jiangsu Hengrui Co, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib jiangsu hengrui co/product/Jiangsu Hengrui Medicine
Average 90 stars, based on 1 article reviews
apatinib jiangsu hengrui co - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
apatinib  (Selleck Chemicals)
94
Selleck Chemicals apatinib
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
apatinib - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
apatinib mesylate  (Jiangsu Hengrui Medicine)
90
Jiangsu Hengrui Medicine apatinib mesylate
( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 <t>inhibitor</t> <t>AS1842856</t> (10 mg/kg, every 2 days) or the VEGFR inhibitor <t>Apatinib</t> (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .
Apatinib Mesylate, supplied by Jiangsu Hengrui Medicine, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apatinib mesylate/product/Jiangsu Hengrui Medicine
Average 90 stars, based on 1 article reviews
apatinib mesylate - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 inhibitor AS1842856 (10 mg/kg, every 2 days) or the VEGFR inhibitor Apatinib (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer

doi: 10.7554/eLife.102433

Figure Lengend Snippet: ( A–C ) Metabric database analysis in BCIP revealed high expression levels of STAMBPL1, FOXO1, and GRHL3 in TNBC ( n = 319) compared with non-TNBC ( n = 1661). ( D ) The effect of STAMBPL1 overexpression in HCC1806 cells was detected by Western blotting. ( E ) Nude mice with tumors received the FOXO1 inhibitor AS1842856 (10 mg/kg, every 2 days) or the VEGFR inhibitor Apatinib (50 mg/kg, every 2 days) or a combination of both treatments. The effect of the drug treatments on the transplanted tumors was assessed by imaging the tumors. ( F, G ) The weight and growth of the transplanted tumors in the nude mice were statistically analyzed. The vector control group and the STAMBPL overexpression group were compared. The nondrug group and the combined drug group in the vector control group were compared. The nondrug group and the combined drug group in the STAMBPL overexpression group were compared (n = 8). ( H ) The final weights of the nude mice were statistically analyzed (n = 4). Mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, t- test. Figure 8—source data 1. PDF file containing original western blots for , indicating the relevant bands and treatments. Figure 8—source data 2. Original files for western blot analysis displayed in .

Article Snippet: AS1842856 (Cat#HY-100596) and apatinib (Cat#HY-13342S) were purchased from MCE (New Jersey, USA).

Techniques: Expressing, Over Expression, Western Blot, Imaging, Plasmid Preparation, Control